[go: up one dir, main page]

PE20081761A1 - Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos - Google Patents

Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos

Info

Publication number
PE20081761A1
PE20081761A1 PE2008000304A PE2008000304A PE20081761A1 PE 20081761 A1 PE20081761 A1 PE 20081761A1 PE 2008000304 A PE2008000304 A PE 2008000304A PE 2008000304 A PE2008000304 A PE 2008000304A PE 20081761 A1 PE20081761 A1 PE 20081761A1
Authority
PE
Peru
Prior art keywords
alkyl
halo
alcoxy
agonists
compounds
Prior art date
Application number
PE2008000304A
Other languages
English (en)
Inventor
Kevin D Mccormick
Christopher W Boyce
Pietro Mangiaracina
Younong Yu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39590425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081761(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20081761A1 publication Critical patent/PE20081761A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE NAFTENO E INDANO DE FORMULA (I) DONDE J4 ES UN COMPUESTO DE FORMULA (a), (b) O (c), DONDE Z ES -[C(RC)(RC)]x- EN DONDE x ES DE 1 A 3; RC ES H O ALQUILO; A ES UN ANILLO HETEROARILO, HETEROCICLILO O HETEROCICLENILO DE 5 MIEMBROS; R4 ES H, CN, HALO, ALCOXI, ENTRE OTROS; R4' ES H, HALO, ALQUILO, CICLOALCOXI, ENTRE OTROS; R6 ES H, CN, CICLOALQUILO, ALCOXI, ENTRE OTROS; R13 ES H, ALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS; R14 ES H, ALQUILO, HALO, CN O ALCOXI; m ES 0 O 1; z ES DE 0 A 5; J1, J2 Y J3 SON CADA UNO -N-, -N(O)- O -C(R2)-, EN DONDE R2 ES H, OH, HALO, CN, NO2, ENTRE OTROS; === ES UN ENLACE SIMPLE O DOBLE; n Y w SON CADA UNO DE 1 A 3; R1 ES -[C(Ra)(Rb)]qNR7R7', -[C(Ra)(Rb)]qON=CR7R7', ENTRE OTROS, DONDE Ra Y Rb SON CADA UNO H, ALQUILO, ALCOXI O HALO; R7 ES H, ALQUILO, ALQUINILO, CICLOALQUILO, ENTRE OTROS; R7' ES H, ALQUILO, ARILO, ALQUENILO, ENTRE OTROS; q ES DE 0 A 10; R3 ES H, ALQUENILO, ALQUINILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS LOS COMPUESTOS DE FORMULA (i), (ii), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DE LOS RECEPTORES a2C SIENDO UTILES EN EL TRATAMIENTO DE LA RINITIS ALERGICA, CONGESTION, MIGRANA, GLAUCOMA, ISQUEMIA CARDIACA
PE2008000304A 2007-02-13 2008-02-12 Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos PE20081761A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90106407P 2007-02-13 2007-02-13

Publications (1)

Publication Number Publication Date
PE20081761A1 true PE20081761A1 (es) 2008-12-06

Family

ID=39590425

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000304A PE20081761A1 (es) 2007-02-13 2008-02-12 Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos

Country Status (11)

Country Link
US (1) US8017642B2 (es)
EP (1) EP2398776A1 (es)
JP (1) JP2010518163A (es)
CN (1) CN101657429A (es)
AR (1) AR065309A1 (es)
CA (1) CA2678072A1 (es)
CL (1) CL2008000431A1 (es)
MX (1) MX2009008776A (es)
PE (1) PE20081761A1 (es)
TW (1) TW200843745A (es)
WO (1) WO2008100480A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008777A (es) 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
JP2010518159A (ja) 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α２Ｃアドレナリン受容体アゴニスト
EP2398776A1 (en) 2007-02-13 2011-12-28 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
US8383818B2 (en) 2008-02-21 2013-02-26 Merck Sharp & Dohme Corp. Functionally selective alpha2C adrenoreceptor agonists
WO2010033495A2 (en) * 2008-09-16 2010-03-25 Schering Corporation Functionally selective azanitrile alpha2c adrenoreceptor agonists
US8324213B2 (en) 2008-10-07 2012-12-04 Merck Sharp & Dohme Corp. Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators
CN112125790A (zh) * 2020-10-27 2020-12-25 埃法姆药物研发(宁夏)有限公司 一种7-氯-1-萘醛的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7124691A (en) 1990-02-27 1991-08-29 Ciba-Geigy Ag Benzofurans
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
RU2235092C2 (ru) 1997-12-04 2004-08-27 Оллерган Инк. Замещенные производные имидазола, способ введения активного соединения и способ лечения на основе этих соединений
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
TWI283669B (en) 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
FR2810979B1 (fr) 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
WO2005005781A1 (en) 2003-07-14 2005-01-20 Elthom Enterprises Limited Volume screw machine of rotary type
KR20080039982A (ko) 2005-08-25 2008-05-07 쉐링 코포레이션 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제로서의이미다졸 유도체
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
JP2009506051A (ja) 2005-08-25 2009-02-12 シェーリング コーポレイション α２Ｃアドレナリン受容体アゴニスト
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
WO2007085556A2 (en) 2006-01-27 2007-08-02 F. Hoffmann-La Roche Ag Use of 4-imidazole derivatives for cns disorders
JP2010518159A (ja) 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α２Ｃアドレナリン受容体アゴニスト
MX2009008777A (es) 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
EP2398776A1 (en) 2007-02-13 2011-12-28 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists

Also Published As

Publication number Publication date
EP2398776A1 (en) 2011-12-28
US20100144816A1 (en) 2010-06-10
MX2009008776A (es) 2009-08-25
US8017642B2 (en) 2011-09-13
WO2008100480A1 (en) 2008-08-21
JP2010518163A (ja) 2010-05-27
CA2678072A1 (en) 2008-08-21
CN101657429A (zh) 2010-02-24
TW200843745A (en) 2008-11-16
AR065309A1 (es) 2009-05-27
CL2008000431A1 (es) 2008-08-18

Similar Documents

Publication Publication Date Title
PE20081761A1 (es) Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos
PE20050525A1 (es) Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1
PE20090650A1 (es) Agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
PE20060401A1 (es) Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno
PE20081314A1 (es) COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB
PE20070336A1 (es) Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
PE20080716A1 (es) Coterapia constituida por un derivado de heterociclosulfamida benzofusionado y uno o varios agentes anticonvulsivantes y/o antilepticos
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR065822A1 (es) Derivados de tiazolidina. composiciones farmaceuticas y usos como antagonistas del receptor orexina
PE20081782A1 (es) Agonistas de adrenoreceptores alfa2c
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
AR049696A1 (es) Derivados de indol
PE20061295A1 (es) Derivados de acetileno
PE20040938A1 (es) Compuestos (2-carboxamido)(3-amino)tiofenos
PE20061144A1 (es) DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs)
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20020407A1 (es) Derivados de quinazolina como antagonistas del receptor adrenergico alfa-1
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
PE20050483A1 (es) Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas

Legal Events

Date Code Title Description
FD Application declared void or lapsed